Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients With Advanced or Recurrent, Non-resectable HPV 16-Positive Cervical Cancer

NCT04405349 is registered in ClinicalTrials.gov with Nykode Therapeutics ASA as lead sponsor.

NCT NCT04405349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04405349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients With Advanced or Recurrent, Non-resectable HPV 16-Positive Cervical Cancer
Lead sponsor
Nykode Therapeutics ASA
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2020
Completion date
November 24, 2023
Enrollment
52 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cervix cancer